FIG. 4.
Radio-binding assay analysis of the specificities and biological activities of anti-CCR5 mouse Abs on human CD4+ lymphocytes. (A) CCR5-binding activities of antibodies elicited by systemic or mucosal immunizations with FHV-WT, synthetic cyclic CCR589-102 peptide, or FHV-I2. (B) Radio binding to human CCR5 of serum (Se) IgG, serum IgA, or mucosal (Mu) IgA elicited by mucosal immunization with FHV-WT or FHV-I2. The negative control (Cntr) was an Ig fraction from NMS (20 ng/assay). The positive control was the anti-human CCR5 MAb 2D7. (C) Dose-response curves of CCR5 down-regulation obtained by incubating human CD4+ lymphocytes for 48 h with the indicated dilutions of FHV-I2 or FHV-WT antisera. Negative controls were target cells incubated only with the secondary Ab (RAM-FITC).